Fedratinib Re-emerges as FDA-Approved Treatment of Myelofibrosis
Andrew Kuykendall, MD, discusses the background to the JAK2 inhibitor fedratinib (Inrebic), which was approved by the FDA in August 2019 for the treatment of patients with intermediate-2 or high-risk primary or secondary myelofibrosis, including post–polycythemia vera or post–essential thrombocythemia MF.
Andrew Kuykendall, MD, assistant member at the Moffitt Cancer Center, discusses the background to the JAK2 inhibitor fedratinib (Inrebic), which wasapproved by the FDA in August 2019 for the treatment of patients with intermediate-2 or high-risk primary or secondary myelofibrosis(MF), including postpolycythemia vera or post–essential thrombocythemia MF.
Kuykendall says fedratinib has an interesting story. It’s a relatively old drug that had previously been through extensive clinical trials years ago and has now re-emerged. He calls this a rising-from-the-ashes story to describe the evolution of fedratinib and its move toward the treatment landscape for patients with MF.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
